Evidence map›Paper›PMID 29661159›Full record

ArticleBMC cancer2018

Active DNA end processing in micronuclei of ovarian cancer cells.

Zizhi Tang, Juan Yang, Xin Wang, Ming Zeng, Jing Wang, Ao Wang, Mingcai Zhao, Liandi Guo, Cong Liu, Dehua Li and 1 more

Open access · goldAbstract read
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 21 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Zizhi TangDepartment of Pharmacology, West China Second University Hospital, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Ministry of Education), Sichuan University, Chengdu, 610041, People's Republic of China.
Juan YangDepartment of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.
Xin WangDepartment of Pharmacology, West China Second University Hospital, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Ministry of Education), Sichuan University, Chengdu, 610041, People's Republic of China.
Ming ZengDepartment of Pharmacology, West China Second University Hospital, Key Laboratory of Birth Defects and Related Diseases of Women and Children (Ministry of Education), Sichuan University, Chengdu, 610041, People's Republic of China.
Jing WangDepartment of Laboratory Medicine, Suining Central Hospital, 629000, Suining, People's Republic of China.
Ao WangDepartment of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, 610041, People's Republic of China.
Mingcai ZhaoDepartment of Laboratory Medicine, Suining Central Hospital, 629000, Suining, People's Republic of China.
Liandi GuoCollege of Pharmacy, Southwest Minzu University, No.16 South Section 4, Yihuan Road, Chengdu, 610041, People's Republic of China.
Cong LiuDepartment of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, 610041, People's Republic of China. congliu@scu.edu.cn.
Dehua LiDepartment of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, 610041, People's Republic of China. 562372162@qq.com.
Jie ChenDepartment of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, 610041, People's Republic of China. cjzb@sina.com.
Sichuan University · CNWest China Second University Hospital of Sichuan University · CNSuizhou Central Hospital · CNSouthwest Minzu University · CN

Funding

Department of Science and Technology of Sichuan Province 2014KJT060-2014SZDepartment of Science and Technology of Sichuan Province 2017FZ0034Department of Science and Technology of Sichuan Province NO.2017ZR0169Ministry of Science and Technology of China 2013CB911000NSF China 31171319NSF China 31471276
6 · The paper itself

Abstract

backgroundOvarian cancer is one of the most deadly gynecological malignancies and inclined to recurrence and drug resistance. Previous studies showed that the tumorigenesis of ovarian cancers and their major histotypes are associated with genomic instability caused by defined sets of pathogenic mutations. In contrast, the mechanism that influences the development of drug resistance and disease recurrence is not well elucidated. Solid tumors are prone to chromosomal instability (CIN) and micronuclei formation (MN). Although MN is traditionally regarded as the outcome of genomic instability, recent investigation on its origin and final consequences reveal that the abnormal DNA metabolism in MN is a driver force for some types of catastrophic genomic rearrangements, accelerating dramatic genetic variation of cancer cells.

methodsWe used Indirect Immunofluorescent staining to visualize micronuclei and activation of DNA repair factors in ovarian cancer cell lines and biopsies.

resultsWe show that ovarian cancer cells are disposed to form micronuclei upon genotoxic insults. Double strand DNA breaks (DSBs)-triggered insurgence of micronuclei is associated with unrepaired chromosomes passing through mitosis. According to their morphology and DNA staining, micronuclei compartments are divided into early and late stages that can be further characterized by differential staining of γH2AX and 53BP1. We also show that MN compartments do not halt controlled DNA metabolism as sequestered nuclear repair factors are enriched at DNA breaks in MN compartments and efficiently process DNA ends to generate single-stranded DNA (ssDNA) structures. Interestingly, unknown factors are required for DNA end processing in MN in addition to the nuclear resection machinery. Finally, these hallmarks of micronuclei evolution depicted in cell culture were recapitulated in different stages of ovarian cancer biopsies.

conclusionsIn aggregate, our findings demonstrate that ovarian cancer cells are inclined to form micronuclei that undergo robust DNA metabolism and generate ssDNA structures, potentially destabilizing genomic structures and triggering genetic variation.

Indexed as

DNA Breaks, Double-StrandedDNA DamageDNA End-Joining RepairDNA, NeoplasmFemaleGenomic InstabilityHumansMicronuclei, Chromosome-DefectiveMutationNeoplasm Recurrence, LocalOvarian NeoplasmsDNA, NeoplasmDNA damageMicronucleusOvarian cancerssDNA

Identifiers

PMID29661159
PMCPMC5902893
OpenAlexW2804107560

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.